Koller H, Zitt E, Staudacher G, Neyer U, Mayer G, Rosenkranz A R
Klinische Abteilung für Nephrologie, Universitätsklinik für Innere Medizin, Leopold-Franzens-Universität, Innsbruck, Austria.
Clin Nephrol. 2004 May;61(5):337-43. doi: 10.5414/cnp61337.
Parathyroidhormone (PTH) measurement is important in the evaluation of bone disease in patients with chronic renal failure. Large carboxyl-terminal PTH fragments (C-PTH) cross-react with second-generation PTH assays, lead to an overestimation of biologically active PTH, and are evaluated by a combination of second- and third-generation PTH assays. The aim of our study was to examine whether the use of 4 different PTH assays of putatively same specificity leads to comparable results detecting C-PTH fragments.
In 70 chronic dialysis patients, total PTH and PTH(1-84) were measured in parallel by 4 novel PTH assays (Nichols Advantage Intact PTH and Bio-Intact PTH Chemiluminescence Assay, Nichols Institute Diagnostics, USA, DUO Total and CAP PTH IRMA, Scantibodies Laboratory, USA). The C-PTH concentration was quantitated by subtracting PTH(1-84) from total PTH. Consecutively, the PTH(1-84)/C-PTH ratio was calculated.
Nichols Intact PTH and DUO Total PTH assays were highly correlated (r = 0.985), as well as Nichols Bio-Intact and DUO CAP assays (r = 0.984). However, total PTH values measured by the Nichols assay were 30% higher (median (range): 185 (9.9 - 2,332) versus 130 (2.3 - 1,271.1) pg/ml, p < 0.01). PTH(1-84) values, measured by the Nichols Bio-Intact PTH assay were 8% higher compared to the Scantibodies CAP assay (median (range): 79.6 (7.5 - 1,060.9) versus 73.7 (4.4 - 918.9) pg/ml, p = NS). Thirty-six patients had a ratio < 1 measured by the Nichols assays, whereas only 8 patients showed the same ratio when measured by the Scantibodies assays. In 28 patients (40%), contradictory PTH(1-84)/C-PTH ratios were found, showing a ratio < 1 when measured by the Nichols assays, but > 1 when the Scantibodies assays were used.
In conclusion, our results suggest that the PTH(1-84)/C-PTH ratio cannot be equally used as a predictor of bone turnover when different PTH assays are used. Depending on those assays, differences in total PTH values mathematically lead to varying amounts of C-PTH fragments resulting in variable, even contradictory PTH(1-84)/C-PTH ratios.
甲状旁腺激素(PTH)检测对于评估慢性肾衰竭患者的骨病至关重要。大的羧基末端PTH片段(C-PTH)与第二代PTH检测方法存在交叉反应,导致对生物活性PTH的高估,需通过第二代和第三代PTH检测方法联合评估。我们研究的目的是检验使用4种假定特异性相同的不同PTH检测方法检测C-PTH片段时是否能得到可比的结果。
对70例慢性透析患者,采用4种新型PTH检测方法(美国Nichols Institute Diagnostics公司的Nichols Advantage完整PTH和生物完整PTH化学发光检测法,美国Scantibodies Laboratory公司的DUO总PTH和CAP PTH免疫放射分析)同时检测总PTH和PTH(1 - 至84)。通过从总PTH中减去PTH(1 - 至84)来定量C-PTH浓度。随后,计算PTH(1 - 至84)/C-PTH比值。
Nichols完整PTH检测法与DUO总PTH检测法高度相关(r = 0.985),Nichols生物完整PTH检测法与DUO CAP检测法也高度相关(r = 0.984)。然而,Nichols检测法测得的总PTH值高30%(中位数(范围):185(9.9 - 2332)对130(2.3 - 1271.1)pg/ml,p < 0.01)。Nichols生物完整PTH检测法测得的PTH(1 - 至84)值比Scantibodies CAP检测法高8%(中位数(范围):79.6(7.5 - 1060.9)对73.7(4.4 - 918.9)pg/ml,p = 无显著差异)。36例患者经Nichols检测法测得的比值<1,而经Scantibodies检测法测得相同比值的患者仅8例。在28例患者(40%)中,发现PTH(1 - 至84)/C-PTH比值相互矛盾:经Nichols检测法测得的比值<1,但使用Scantibodies检测法时>1。
总之,我们的结果表明,当使用不同的PTH检测方法时,PTH(1 - 至84)/C-PTH比值不能同等地用作骨转换的预测指标。取决于这些检测方法,总PTH值的差异在数学上导致不同数量的C-PTH片段,从而产生可变的、甚至相互矛盾的PTH(1 - 至84)/C-PTH比值。